Vesilute
Longevity & Cellular HealthAlso known as: Glu-Asp, ED, L-Glutamyl-L-Aspartic Acid, Urinary Tract Bioregulator
Mechanism
Vesilute is a dipeptide bioregulator that primarily targets smooth muscle tissue, particularly in the urinary tract and blood vessels. It works by interacting with chromatin structures in cell nuclei, helping to reactivate genes that become silenced during aging. Users report improvements in urinary function, blood flow, and smooth muscle relaxation. It may also support prostate health indirectly by improving vascular function in the pelvic region.
Technical detail
Synthetic dipeptide (L-glutamyl-L-aspartic acid, Glu-Asp) developed by Khavinson as a bioregulator for smooth muscle and vascular tissue. Proposed mechanism: direct interaction with heterochromatin regions in cell nuclei, promoting chromatin decondensation to reactivate genes silenced during cellular aging (consistent with Khavinson peptide bioregulation theory). Experimental evidence suggests relaxation of smooth muscle tissue throughout the body — potentially aiding blood pressure regulation, nutrient delivery, and oxygenation via improved vascular function. Also studied for urinary tract function and bladder smooth muscle support.
Effects
VASCULAR: Proposed relaxation of smooth muscle tissue in blood vessels, potentially aiding blood pressure regulation. Promotes better nutrient delivery and oxygenation via improved vascular function (proposed). UROLOGICAL: Primary clinical application per Khavinson literature. Regulates urinary tract function — improves bladder smooth muscle function. Supports urinary flow and reduces symptoms associated with bladder dysfunction. MUSCULOSKELETAL (SMOOTH MUSCLE): General smooth muscle bioregulator — effects extend to any tissue with smooth muscle components (blood vessels, bladder, GI tract). Promotes chromatin decondensation in smooth muscle cells, reactivating genes silenced during aging (Khavinson peptide-DNA interaction hypothesis). REPRODUCTIVE: May enhance prostate health indirectly via improved pelvic vascular function. Improved blood flow supports reproductive organ health. NEUROLOGICAL: No direct neurological effects documented. ENDOCRINE: No direct endocrine effects. METABOLIC: No direct metabolic effects. Improved vascular function may contribute to better metabolic substrate delivery. IMMUNE: No direct immune effects documented. Tier 3: Used by practitioners for urinary symptoms and vascular support, particularly in elderly patients. Often paired with Prostamax for comprehensive urogenital health in men. Some practitioners use it for peripheral circulation improvement.
Practitioner Guide
DOSING TIPS: Standard Khavinson bioregulator protocol: 10-20mg subcutaneous injection daily for 10-30 days, repeated 2-3 times per year. Also available as oral capsules — 1-2 capsules daily for 30 days. RECONSTITUTION: Lyophilized powder — reconstitute with bacteriostatic water. INJECTION SITE: Subcutaneous — abdominal fat pad or thigh. TIMING: No specific timing requirements. SUPPLEMENT SYNERGIES: Stack with Prostamax for comprehensive urogenital support (Vesilute for smooth muscle/vascular + Prostamax for prostate tissue). Magnesium (400mg/day) — supports smooth muscle relaxation. Beetroot extract/nitrates — support nitric oxide production for vascular function. L-citrulline (3-6g/day) — enhances nitric oxide synthesis. CYCLING: Course-based — 10-30 days on, 3-6 month break. 2-3 courses per year. STACKING: Urogenital: Vesilute + Prostamax + Zinc. Vascular: Vesilute + Vesugen + L-citrulline. Anti-aging: Vesilute + Epithalon + Thymalin. CONTRAINDICATION NUANCES: Hypotension — smooth muscle relaxation may lower blood pressure further. Patients on blood pressure medications — inform prescribing physician. STORAGE: Lyophilized — room temperature or refrigerated. PATIENT EDUCATION: Vesilute supports smooth muscle function throughout the body — particularly in blood vessels and the urinary tract. Think of it as helping these tissues maintain youthful flexibility and responsiveness. Effects are gradual over the course of treatment. Best suited for age-related urinary or circulation concerns.
Research Summary
TIER 1 (Gold Standard): None. TIER 2 (Strong): Khavinson VK — publications on dipeptide bioregulators and organ-specific effects. Peptide-DNA interaction studies. TIER 3 (Moderate): Russian clinical data on urological bioregulator use. Practitioner protocols from anti-aging clinics. Post-marketing surveillance from Russia. Community reports of urinary symptom improvement. KEY FINDINGS: (1) Dipeptide bioregulator targeting smooth muscle is a plausible concept. (2) Very limited published data. (3) Safety profile appears good based on clinical use history. GAPS: No Western trials. Mechanism not characterized. Bioavailability unknown. Comparison with established urological treatments. ACTIVE TRIALS: None.